

# István Bitter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6924152/publications.pdf>

Version: 2024-02-01

114  
papers

9,771  
citations

81900

39  
h-index

37204

96  
g-index

117  
all docs

117  
docs citations

117  
times ranked

12770  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study identifies five new schizophrenia loci. <i>Nature Genetics</i> , 2011, 43, 969-976.	21.4	1,758
2	Common variants conferring risk of schizophrenia. <i>Nature</i> , 2009, 460, 744-747.	27.8	1,572
3	Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. <i>British Journal of Psychiatry</i> , 2009, 194, 204-211.	2.8	1,200
4	Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. <i>JAMA Psychiatry</i> , 2019, 76, 893.	11.0	472
5	Updated European Consensus Statement on diagnosis and treatment of adult ADHD. <i>European Psychiatry</i> , 2019, 56, 14-34.	0.2	330
6	Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. <i>Lancet</i> , 2017, 389, 1103-1113.	13.7	249
7	Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. <i>European Neuropsychopharmacology</i> , 2004, 14, 457-470.	0.7	245
8	Common variants at VRK2 and TCF4 conferring risk of schizophrenia. <i>Human Molecular Genetics</i> , 2011, 20, 4076-4081.	2.9	193
9	Mental health research priorities for Europe. <i>Lancet Psychiatry</i> , 2015, 2, 1036-1042.	7.4	158
10	Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. <i>World Psychiatry</i> , 2022, 21, 248-271.	10.4	156
11	Stratified medicine for mental disorders. <i>European Neuropsychopharmacology</i> , 2014, 24, 5-50.	0.7	152
12	Expanding the range of ZNF804A variants conferring risk of psychosis. <i>Molecular Psychiatry</i> , 2011, 16, 59-66.	7.9	140
13	Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. <i>European Neuropsychopharmacology</i> , 2013, 23, 196-204.	0.7	137
14	Attention deficit hyperactivity disorder (ADHD): gender- and age-related differences in neurocognition. <i>Psychological Medicine</i> , 2009, 39, 1337-1345.	4.5	122
15	Haloperidol Blood Levels and Clinical Effects. <i>Archives of General Psychiatry</i> , 1992, 49, 354.	12.3	114
16	Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 173-180.	4.8	114
17	Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 1137.	2.1	114
18	A blind spot on the global mental health map: a scoping review of 25 years' development of mental health care for people with severe mental illnesses in central and eastern Europe. <i>Lancet Psychiatry</i> , 2017, 4, 634-642.	7.4	112

#	ARTICLE	IF	CITATIONS
19	ROAMER: roadmap for mental health research in Europe. <i>International Journal of Methods in Psychiatric Research</i> , 2014, 23, 1-14.	2.1	109
20	P300 deficits in adults with attention deficit hyperactivity disorder: a meta-analysis. <i>Psychological Medicine</i> , 2011, 41, 1529-1538.	4.5	101
21	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. <i>European Neuropsychopharmacology</i> , 2019, 29, 971-985.	0.7	93
22	Common variant at 16p11.2 conferring risk of psychosis. <i>Molecular Psychiatry</i> , 2014, 19, 108-114.	7.9	85
23	Effectiveness of Antipsychotic Treatments for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 312-321.	2.2	73
24	Prevalence and comorbidity of affective disorders in persons making suicide attempts in Hungary: importance of the first depressive episodes and of bipolar II diagnoses. <i>Journal of Affective Disorders</i> , 2003, 76, 113-119.	4.1	64
25	The measurement of subjective experience in schizophrenia: The subjective deficit syndrome scale. <i>Comprehensive Psychiatry</i> , 1990, 31, 216-226.	3.1	63
26	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. <i>European Neuropsychopharmacology</i> , 2019, 29, 947-959.	0.7	60
27	Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary. <i>Schizophrenia Research</i> , 2014, 152, 246-254.	2.0	59
28	Drug Effect Prediction by Polypharmacology-Based Interaction Profiling. <i>Journal of Chemical Information and Modeling</i> , 2012, 52, 134-145.	5.4	57
29	Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients. <i>International Clinical Psychopharmacology</i> , 2005, 20, 19-21.	1.7	55
30	Executive function in deficit schizophrenia: What do the dimensions of the Wisconsin Card Sorting Test tell us?. <i>Schizophrenia Research</i> , 2010, 122, 85-93.	2.0	53
31	Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study. <i>European Psychiatry</i> , 2017, 45, 97-103.	0.2	50
32	Intramuscular Olanzapine and Intramuscular Haloperidol in Acute Schizophrenia: Antipsychotic Efficacy and Extrapyramidal Safety during the First 24 Hours of Treatment. <i>Canadian Journal of Psychiatry</i> , 2003, 48, 716-721.	1.9	49
33	Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). <i>European Psychiatry</i> , 2005, 20, 403-408.	0.2	47
34	How do different diagnostic criteria, age and gender affect the prevalence of attention deficit hyperactivity disorder in adults? An epidemiological study in a Hungarian community sample. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 287-296.	3.2	46
35	Multivariate patterns of EEG microstate parameters and their role in the discrimination of patients with schizophrenia from healthy controls. <i>Psychiatry Research</i> , 2020, 288, 112938.	3.3	45
36	Prescribing for Inpatients with Schizophrenia: An International Multi-Center Comparative Study. <i>Pharmacopsychiatry</i> , 2003, 36, 143-149.	3.3	44

#	ARTICLE	IF	CITATIONS
37	Genes and environments in schizophrenia: The different pieces of a manifold puzzle. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 2424-2437.	6.1	44
38	Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST). <i>Journal of Clinical Psychiatry</i> , 2011, 72, 955-961.	2.2	43
39	Alterations in resting-state gamma activity in patients with schizophrenia: a high-density EEG study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 429-437.	3.2	41
40	Relationship between the brief psychiatric rating scale and the scale for the assessment of negative symptoms: A study of their correlation and redundancy. <i>Psychiatry Research</i> , 1991, 36, 129-139.	3.3	40
41	Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. <i>European Psychiatry</i> , 2012, 27, 114-128.	0.2	39
42	General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 107-115.	3.2	39
43	Association study of <i>NRG1</i> , <i>DTNBP1</i> , <i>RGS4</i> , <i>G72/G30</i> , and <i>PIP5K2A</i> with schizophrenia and symptom severity in a Hungarian sample. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 792-801.	1.7	37
44	How to find the way out from four rooms? The learning of "chaining" associations may shed light on the neuropsychology of the deficit syndrome of schizophrenia. <i>Schizophrenia Research</i> , 2008, 99, 200-207.	2.0	34
45	Associative learning in deficit and nondeficit schizophrenia. <i>NeuroReport</i> , 2008, 19, 55-58.	1.2	34
46	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). <i>Journal of Affective Disorders</i> , 2022, 299, 367-376.	4.1	33
47	Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 529-537.	2.1	32
48	A systematic review of health economic models and utility estimation methods in schizophrenia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 267-275.	1.4	32
49	Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: A nationwide study in Hungary. <i>European Neuropsychopharmacology</i> , 2013, 23, 1383-1390.	0.7	29
50	Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 894-903.	2.6	28
51	László Meduna's Pilot Studies With Camphor Inductions of Seizures. <i>Journal of ECT</i> , 2009, 25, 3-11.	0.6	27
52	Psychiatry in selected countries of Central and Eastern Europe: an overview of the current situation. <i>Acta Psychiatrica Scandinavica</i> , 2006, 114, 223-231.	4.5	26
53	Prevalence of subthreshold forms of psychiatric disorders in persons making suicide attempts in Hungary. <i>European Psychiatry</i> , 2000, 15, 354-361.	0.2	25
54	12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25 mg/day) versus escitalopram (10 mg/day) in out-patients with severe generalized anxiety disorder. <i>European Neuropsychopharmacology</i> , 2018, 28, 970-979.	0.7	25

#	ARTICLE	IF	CITATIONS
55	Adverse reactions to duloxetine in depression. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 839-850.	2.4	24
56	Is ADHD severity in adults associated with the lifetime prevalence of comorbid depressive episodes and anxiety disorders?. <i>European Psychiatry</i> , 2013, 28, 308-314.	0.2	24
57	Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 1917-1924.	5.4	24
58	Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. <i>Schizophrenia Research</i> , 2006, 81, 139-143.	2.0	23
59	Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw083.	2.1	23
60	Measuring Users' Receptivity Toward an Integral Intervention Model Based on mHealth Solutions for Patients With Treatment-Resistant Schizophrenia (m-RESIST): A Qualitative Study. <i>JMIR MHealth and UHealth</i> , 2016, 4, e112.	3.7	23
61	Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. <i>European Neuropsychopharmacology</i> , 2008, 18, 170-180.	0.7	22
62	Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1043-1053.	1.8	22
63	Fearful face recognition in schizophrenia: An electrophysiological study. <i>Schizophrenia Research</i> , 2013, 149, 135-140.	2.0	21
64	Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial. <i>Trials</i> , 2020, 21, 161.	1.6	21
65	Functional impairment in adults positively screened for attention-deficit hyperactivity disorder: The role of symptom presentation and executive functioning. <i>Comprehensive Psychiatry</i> , 2013, 54, 974-981.	3.1	20
66	ADHD: a hidden comorbidity in adult psychiatric patients. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2019, 11, 83-89.	1.7	19
67	Decreased resting gamma activity in adult attention deficit/hyperactivity disorder. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 691-702.	2.6	18
68	Electrodermally differentiated subgroups of anxiety patients. I. Automatic and vigilance characteristics. <i>International Journal of Psychophysiology</i> , 1987, 5, 43-51.	1.0	17
69	Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 71-82.	3.2	16
70	Pharmacological treatment of adult ADHD. <i>Current Opinion in Psychiatry</i> , 2012, 25, 529-534.	6.3	15
71	Replication Study and Meta-Analysis in European Samples Supports Association of the 3p21.1 Locus with Bipolar Disorder. <i>Biological Psychiatry</i> , 2012, 72, 645-650.	1.3	15
72	Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate. <i>BMC Psychiatry</i> , 2013, 13, 71.	2.6	15

#	ARTICLE	IF	CITATIONS
73	Treatment adherence and insight in schizophrenia. <i>Psychiatria Hungarica</i> , 2015, 30, 18-26.	0.2	15
74	State of psychiatry in Hungary. <i>International Review of Psychiatry</i> , 2012, 24, 307-313.	2.8	14
75	Insight and Hostility as Predictors and Correlates of Nonadherence in the European First Episode Schizophrenia Trial. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 258-261.	1.4	14
76	A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania. <i>European Psychiatry</i> , 2006, 21, 1-9.	0.2	13
77	Relating the shape of protein binding sites to binding affinity profiles: is there an association?. <i>BMC Structural Biology</i> , 2010, 10, 32.	2.3	13
78	A proposal for a psychopharmacology "pharmacotherapy catalogue of learning objectives and a curriculum in Europe. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 29-38.	2.6	13
79	A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials?. <i>Translational Psychiatry</i> , 2021, 11, 510.	4.8	13
80	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 826465.	2.6	13
81	Electrophysiological indices of aberrant error-processing in adults with ADHD: a new region of interest. <i>Brain Imaging and Behavior</i> , 2017, 11, 1616-1628.	2.1	12
82	Neural Correlates of Error Monitoring in Adult Attention Deficit Hyperactivity Disorder After Failed Inhibition in an Emotional Go/No-Go Task. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2017, 29, 326-333.	1.8	12
83	The beginnings of modern psychiatric treatment in Europe. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 434-440.	3.2	11
84	Impaired early information processing in adult ADHD: a high-density ERP study. <i>BMC Psychiatry</i> , 2020, 20, 292.	2.6	11
85	Designer drugs in psychiatric practice - a review of the literature and the recent situation in Hungary. <i>Neuropsychopharmacologia Hungarica</i> , 2013, 15, 223-31.	0.1	11
86	Károly Schaffer and his school: The birth of biological psychiatry in Hungary, 1890-1940. <i>European Psychiatry</i> , 2008, 23, 449-456.	0.2	9
87	Convulsive therapy turns 75. <i>British Journal of Psychiatry</i> , 2009, 194, 387-388.	2.8	9
88	The birth of convulsive therapy revisited: A reappraisal of László Meduna's first cohort of patients. <i>Journal of Affective Disorders</i> , 2012, 136, 1179-1182.	4.1	9
89	A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study). <i>European Neuropsychopharmacology</i> , 2018, 28, 185-194.	0.7	9
90	Attention deficit hyperactivity disorder: Last in, first out - delayed brain maturation with an accelerated decline?. <i>European Neuropsychopharmacology</i> , 2020, 34, 65-75.	0.7	9

#	ARTICLE	IF	CITATIONS
91	Altered response-preparation in patients with adult ADHD: A high-density ERP study. <i>Psychiatry Research - Neuroimaging</i> , 2016, 249, 57-66.	1.8	8
92	Suicidal ideation in adult ADHD: Gender difference with a specific psychopathological profile. <i>Comprehensive Psychiatry</i> , 2018, 85, 23-29.	3.1	8
93	Assessment and Treatment of Negative Symptoms in Schizophrenia—A Regional Perspective. <i>Frontiers in Psychiatry</i> , 2021, 12, 820801.	2.6	8
94	How well do patients with schizophrenia track multiple moving targets?. <i>Neuropsychology</i> , 2007, 21, 319-325.	1.3	7
95	Regressive and Intensive Methods of Electroconvulsive Therapy. <i>Journal of ECT</i> , 2007, 23, 229-232.	0.6	7
96	Types of Complaints in Psychiatric and Internal Medical Patients. <i>Psychopathology</i> , 1985, 18, 241-253.	1.5	6
97	Deinstitutionalization in Europe: two recent examples from Germany and Hungary. <i>Psychiatria Danubina</i> , 2010, 22, 406-12.	0.4	6
98	Validity of Reliability. <i>Journal of Nervous and Mental Disease</i> , 2007, 195, 606-613.	1.0	5
99	β-ENDORPHIN ADMINISTRATION TO ACUTE SCHIZOPHRENIC PATIENTS: A DOUBLE BLIND STUDY. <i>Annals of the New York Academy of Sciences</i> , 1982, 398, 460-469.	3.8	4
100	Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO). <i>International Journal of Psychiatry in Clinical Practice</i> , 2006, 10, 78-90.	2.4	4
101	Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD). <i>Applied Research in Quality of Life</i> , 2017, 12, 409-424.	2.4	4
102	ENHANCE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin for Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	1.7	4
103	Elevated Serum Purine Levels in Schizophrenia: A Reverse Translational Study to Identify Novel Inflammatory Biomarkers. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 645-659.	2.1	4
104	Structural Analogues of Clozapine. , 2006, , 297-313.		3
105	Primary Negative Symptoms: Refining the Research Target. <i>Schizophrenia Bulletin</i> , 2021, 47, 1207-1210.	4.3	3
106	Atypical resting-state gamma band trajectory in adult attention deficit/hyperactivity disorder. <i>Journal of Neural Transmission</i> , 2021, 128, 1239-1248.	2.8	3
107	Comparative Effectiveness of Second Generation Long-acting Injectable Antipsychotics Based on Nationwide Database Research in Hungary: An Update. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	1.7	3
108	Atropine Coma. <i>Journal of ECT</i> , 2005, 21, 203-206.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence. <i>Schizophrenia Bulletin</i> , 2022, 48, 1228-1240.	4.3	2
110	Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study. <i>Current Therapeutic Research</i> , 2004, 65, 57-69.	1.2	1
111	Rhythmic movements of chronic akathisia. <i>Biological Psychiatry</i> , 1990, 27, 465-466.	1.3	0
112	Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 28.	1.5	0
113	Eficacia de la monoterapia de clozapina, olanzapina, quetiapina, risperidona y haloperidol en la reducción del comportamiento hostil y agresivo en pacientes ambulatorios tratados por esquizofrenia: un estudio naturalista prospectivo (IC-SOHO). <i>European Psychiatry (Ed Española)</i> , 2006, 13, 70-76.	0.0	0
114	The Options and Limitations of the Brain Fingerprinting Lie Detection Method in the Criminal Proceeding. <i>Magyar Rendészet</i> , 2018, 18, 43-56.	0.1	0